Results 161 to 170 of about 549,947 (276)

Evaluation of a novel role proposal for the use of a physiotherapist navigator in an acute cancer care setting in Ontario: Protocol for a pilot randomized controlled trial. [PDF]

PLoS One
Edward H, Macedo L, Wojkowski S, Mukherjee SD, Smith-Turchyn J.   +4 more
europepmc   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Sisprenatal como instrumento de avaliação da qualidade da assistência à gestante

Revista de Saúde Pública
OBJETIVO: Avaliar a cobertura do Programa de Humanização do Pré-natal e Nascimento segundo o cumprimento dos seus requisitos mínimos e indicadores de processo, comparando as informações do cartão da gestante com os do Susprenatal.
Carla Betina Andreucci, Jose Guilherme Cecatti, Camila Elias Macchetti, Maria Helena Sousa   +3 more
doaj  

Determining the Impact of a Physiotherapist-Led Primary Care Model for Hip and Knee Pain: Protocol and Analysis Plan for a Cluster Randomized Controlled Trial With Process Evaluation. [PDF]

JMIR Res Protoc
Miller J, Donnelly C, McClintock C, Varette K, Camargo Y, Marsh J, Taljaard M, Mamun MSA, Bacchus G, Barber D, Cooper L, French S, Green M, Hill J, MacDermid J, Norman K, Richardson J, Tranmer J, Wideman T.   +18 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Endotracheal Tube Repositioning Frequency for Preventing Oral Mucosal Pressure Injuries in Intensive Care Units: A Randomised Controlled Trial Study Protocol. [PDF]

Nurs Crit Care
Ozdemır E, Korkmaz F, Derelı N.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Effect of a French Experiment of Team Work between General Practitioners and Nurses on Efficacy and Cost of Type 2 Diabetes Patients Care [PDF]

This study aims to assess the efficacy and the cost of a French team work experiment between nurses and GPs for the managing of type 2 diabetes patients.
Engin Yilmaz, Philippe Le Fur, Yann Bourgueil, Julien Mousquès   +3 more
core  

Nursing care management or nursing case management? A scoping review to identify models, roles, and advantages. [PDF]

Nurs Manage
Martella P, Rossi N, Schiavoni E, Napolitano D.   +3 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source